Progress Update for TPM Cannabinoid Development Program
Released
Released
Announcement PDF
ASX Announcement
20 August 2020
ASX Market Announcements
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000
Progress Update for TPM® Cannabinoid Development Program
Melbourne, Australia, 20 August 2020 - Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the
“Company”), today announces that it is proceeding to the next phase of the recently announced cannabinoid
development program. The decision to move forward was made possible after in vitro studies confirmed
increased cannabidiol (CBD) dispersibility and solubilisation from TPM® cannabidiol formulations in simulated
gastro-intestinal digestions.
As presented to the market in June, Avecho has begun the development of pharmaceutical cannabinoid
products combined with its TPM® technology. These products aim to increase the oral absorption of
cannabinoids, to overcome limitations associated with poor bioavailability and high variability in absorption,
and improve the cost to patients.
This development program consists of three main components; (i) in vitro testing in simulated gastrointestinal digestions, (ii) animal studies to assess in vivo bioavailability of candidate formulations, and (iii)
subsequent human trials testing the best formulations.
Researchers at Bioneer:FARMA, located within the University of Copenhagen, have completed the first round
of formulation testing in vitro . Various formulations containing TPM® were assessed for their ability to
solubilize CBD during simulated gastro-intestinal digestion. Solubility of drug molecules in the intestinal space
is required for absorption, and this in vitro model pioneered by researchers at the University of
Copenhagen, can predict formulations that produce improved oral bioavailability in-vivo.
CBD administered in a commercial formulation vehicle was found to have very poor gastric and intestinal
solubility: a finding that correlates well with the poor oral bioavailability reported for CBD in the literature.
As predicted, test formulations containing TPM® were found to significantly increase the solubilisation of
CBD during gastric and intestinal in vitro digestion, suggesting the potential for improved oral bioavailability
in animals and patients.
Formulations identified in these experiments are now scheduled for testing in animal studies. These
experiments will characterize the CBD absorption profile after oral administration in vivo , and identify a
formulation to take forward into human testing. The animal studies are scheduled to begin in the coming
weeks.
Dr Paul Gavin, Chief Executive Officer of Avecho, said: “We are happy to have successfully passed this first
step with a demonstrated increase in drug solubilisation during in vitro digestion. The coming months will
determine whether this increase in gastro-intestinal solubilissolation produces a commensurate increase in
oral bioavailability”.
Data from both the in vitro and in vivo animal studies will not only be used to support the clinical development
of Avecho’s own pharmaceutical products, but also supplementary licensing opportunities for TPM® allowing
medicinal cannabis suppliers to differentiate their own products.
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
For enquiries, please contact
Ms Melanie Leydin
Company Secretary
Avecho Biotechnology Limited
+61 3 9002 5000
This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.
About Avecho
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products
using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived
from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and
oral, dermal and transdermal absorption of drugs and nutrients.
Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the
human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.
See more here - avecho.com.au
Forward-Looking Statements
Certain statements in this announcement are forward looking statements. Forward looking statements can
generally be identified by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “intend”,
“plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward-looking statements
speak only as at the date of this announcement. These statements are based on current expectations and
beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that
could cause the actual results, performances and achievements to differ materially from any expected future
results, performance or achievements expressed or implied by such forward looking statements.
No representation, warranty or assurance (express or implied) is given or made by AVE that the forwardlooking statements contained in this announcement are accurate, complete, reliable or adequate or that they
will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, AVE and
its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or
completeness of the forward looking statements and exclude all liability whatsoever (including negligence)
for any direct or indirect loss or damage which may be suffered by any person as a consequence of any
information in this announcement or any error or omission therefrom.
Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, AVE disclaims
any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in
these materials to reflect any change in expectations in relation to any forward looking statements or any
change in events, conditions or circumstances on which any statement is based. Nothing in these materials
shall under any circumstances create an implication that there has been no change in the affairs of AVE since
the date of the announcement.
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
Share your feedback
Discover